Wall Street analyst estimates for Bone Biologics Corporation (BBLG): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Bone Biologics Corporation, a medical device enterprise, specializes in fostering bone regeneration for spinal fusion, leveraging its advanced recombinant human protein technology. Its flagship product, NELL-1/DBX, is a unique combination of an osteostimulative recombinant protein designed for precise, targeted control over bone regrowth.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-13 | $-0.19 | ||
| 2026-08-14 | $-0.43 | $-0.43 | +0.0% |
| 2026-05-14 | $-0.43 | $-0.43 | +0.0% |
| 2026-03-02 | $-0.58 | $-0.34 | -70.6% |
| 2025-11-14 | $-0.37 | $-1.23 | +69.9% |
| 2025-08-14 | $-1.33 | $-0.58 | -129.3% |
| 2025-05-13 | $-0.32 | $-3.24 | +90.1% |
| 2025-03-05 | $-0.48 | $-0.65 | +26.2% |
Valuation Ratios
| Price / Book | 0.25 |
| EV / EBITDA | 1.38 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $700 | $96 | $96 | $50 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -$700 | -$96 | -$96 | -$50 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research & Development | $11.6M | -$1.2M | $104490 | $1.1M | $340672 | $82044 | $1.6M | $6.9M | $2.1M | $1.1M |
| Selling, General & Admin | $6.2M | $3.8M | $2.7M | $1.4M | $484342 | $1.0M | $2.1M | $2.5M | $2.1M | $2.2M |
| Operating Expenses | $17.8M | $2.6M | $2.8M | $2.4M | $825014 | $1.1M | $3.7M | $9.4M | $4.2M | $3.2M |
| Operating Income | -$20.4M | -$2.6M | -$2.8M | -$2.4M | -$825014 | -$1.1M | -$3.7M | -$9.4M | -$4.2M | -$3.2M |
| EBITDA | -$20.4M | -$2.6M | -$2.8M | -$2.4M | -$825014 | -$805576 | -$752906 | $479572 | $107161 | -$3.1M |
| Interest Expense | $2.6M | $4.4M | $1.2M | $975774 | $998076 | $805109 | $731714 | 0 | 0 | 0 |
| Pre-tax Income | -$21.0M | -$7.0M | -$4.4M | -$3.4M | -$1.8M | -$1.6M | -$1.5M | -$8.9M | -$4.1M | -$3.1M |
| Income Tax | $2243 | $1600 | $1729 | $1603 | $1600 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$25.9M | -$7.1M | -$4.4M | -$3.4M | -$1.8M | -$1.6M | -$1.5M | -$8.9M | -$4.1M | -$3.1M |
| EPS | $-24840.00 | $-6480.00 | $-3173.58 | $-66.97 | $-35.68 | $-37.35 | $-31.15 | $-34.01 | $-4.83 | $-2.65 |
| EPS (Diluted) | $-24840.00 | $-6480.00 | $-3173.58 | $-66.97 | $-35.68 | $-37.35 | $-31.20 | $-34.01 | $-4.83 | $-2.65 |
| Shares Outstanding (Diluted) | $1045 | $1081 | $1396 | $51138 | $51138 | $43127 | $47658 | $263137 | $1.5M | $1.2M |
Price
| Price | $0.54 |
| Market Cap | $1M |
| Exchange | NASDAQ |
| Country | US |
Related companies: BDRX · DHAI · GCTK · HSCS · INM · MOVE · NAOV
Explore sector: Healthcare · Biotechnology
More sections of BBLG: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks